Ipamorelin
Also called Ipamorelin acetate.
Ipamorelin has no FDA-approved product. This page cites 3 sources, and the strongest evidence comes from human trials.
- Status
- No FDA-approved product
- Form
- Injection
- Half-life
- Not modeled
- Strongest evidence
- Human trials
- Cited claims
- 2
- Last updated
- November 6, 2026
What the evidence says
Each claim names the kind of study behind it, what it can't tell you, and where it comes from.
Human trials
A randomized placebo-controlled intravenous study in healthy men characterized an acute GH response to ipamorelin.
Limits: A hormone response does not establish clinical benefit for growth hormone deficiency, body composition, recovery, or aging. The report did not specify the salt form. Intravenous findings do not establish a subcutaneous regimen.
Human trials
A phase 2 placebo-controlled trial after bowel resection found no statistically significant improvement in time to tolerate a solid meal with intravenous ipamorelin.
Limits: The study enrolled 117 surgical patients, with 114 in the safety and modified intent-to-treat populations. It was small and clinically heterogeneous. A numerical difference was not proof of benefit. The tested salt form was unspecified.
Regulatory status
United States
As of November 6, 2026, ipamorelin and ipamorelin acetate have no FDA-approved drug product. FDA has reviewed them for compounding; that review is not approval.